Biodistribution study and identification of inflammation sites using 99mTc-labelled stealth pH-sensitive liposomes

Carmo, Vildete A.S.; Ferrari, Cristiano S.; Reis, Eduardo C. O.; Ramaldes, Gilson Andrade; Pereira, Maira Alves; Oliveira, Mônica Cristina; Cardoso, Valbert Nascimento

doi:10.1097/mnm.0b013e3282f1bc0d

Cited by 23 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large number of novel nanotherapeutics is also involved in ongoing clinical trials (8) and under investigation for the treatment of specific types of cancers (9,10).…”

Section: Introductionmentioning

confidence: 99%

Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration

Grattoni¹,

Shen²,

Fine³

et al. 2010

Pharm Res

View full text Add to dashboard Cite

show abstract

“…A large number of novel nanotherapeutics is also involved in ongoing clinical trials (8) and under investigation for the treatment of specific types of cancers (9,10).…”

Section: Introductionmentioning

confidence: 99%

Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration

Grattoni¹,

Shen²,

Fine³

et al. 2010

Pharm Res

View full text Add to dashboard Cite

show abstract

“…The different release kinetics of F1AG and F3AG were found to be due to CHEMS, which can modify the NSV bilayer at acidic pH, thus promoting rapid release of payloads. 61 pH modification occurring in an inflamed area can enable rapid release of AG from the F3 formulation, thus having anti-inflammatory and antinociceptive effects similar to those achieved using free AG. Conversely, neutral NSVs (F1AG) are not affected by pH modification and allow slow release of AG in the inflamed area, thus strengthening the antinociceptive effects and reducing edema in murine models.…”

mentioning

confidence: 99%

Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models

Marianecci¹,

Rinaldi²,

Marzio³

et al. 2014

IJN

View full text Add to dashboard Cite

Background: Liquorice extracts demonstrate therapeutic efficacy in treating dermatitis, eczema, and psoriasis when compared with corticosteroids. In this work, nonionic surfactant vesicles (niosomes, NSVs) containing polysorbate 20 (Tween 20), cholesterol, and cholesteryl hemisuccinate at different molar concentrations were used to prepare monoammonium glycyrrhizinate (AG)-loaded NSVs. The anti-inflammatory properties of AG-loaded NSVs were investigated in murine models. Methods: The physicochemical properties of the NSVs were characterized using dynamic light scattering. The fluidity of the lipid bilayer was evaluated by measuring the fluorescence intensity of diphenylhexatriene. The drug entrapment efficiency of AG was assessed using high-performance liquid chromatography. The physicochemical stability of the NSVs was evaluated as a function of time using dynamic light scattering combined with Turbiscan Lab(R) Expert analysis. Serum stability was determined by incubating the NSVs with 10% v/v fetal bovine serum. The cytotoxic effects of the NSVs were investigated in human dermal fibroblasts using the Trypan blue dye exclusion assay (for cell mortality) and an MTT assay (for cell viability). Release profiles for the AG-loaded NSVs were studied in vitro using cellulose membranes. NSVs showing the most desirable physicochemical properties were selected to test for in vivo anti-inflammatory activity in murine models. The anti-inflammatory activity of the NSVs was investigated by measuring edema and nociception in mice stimulated with chemical agents. Results: NSVs showed favorable physicochemical properties for in vitro and in vivo administration. In addition, they demonstrated long-term stability based on Turbiscan Lab Expert analysis. The membrane fluidity of the NSVs was not affected by self-assembling of the surfactants into colloidal structures. Fluorescence anisotropy was found to be independent of the molar ratios of cholesteryl hemisuccinate and/or cholesterol during preparation of the NSVs. The anti-inflammatory AG drug showed no effect on the stability of the NSVs. In vivo experiments demonstrated that AG-loaded NSVs decreased edema and nociceptive responses when compared with AG alone and empty NSVs. In vitro and in vivo results demonstrated that pH sensitive and neutral NSVs show no statistical significant difference. Conclusion: NSVs were nontoxic and showed features favorable for potential administration in vivo. In addition, neutral NSVs showed signs of increased anti-inflammatory and anti-nociceptive responses when compared with AG

show abstract

“…The success of these platforms has led the FDA to approve several investigational new drug (IND) applications for the treatment of several types of cancers. Currently, there are more than 400 ongoing clinical trials involving nanotechnology; the majority of which are for cancer treatment [34]. …”

Section: Nanotechnology Overviewmentioning

confidence: 99%

Enabling individualized therapy through nanotechnology

Sakamoto

Ven

Godin

et al. 2010

Pharmacological Research

188

View full text Add to dashboard Cite

Individualized medicine is the healthcare strategy that rebukes the idiomatic dogma of ‘losing sight of the forest for the trees’. We are entering a new era of healthcare where it is no longer acceptable to develop and market a drug that is effective for only 80% of the patient population. The emergence of “-omic” technologies (e.g. genomics, transcriptomics, proteomics, metabolomics) and advances in systems biology are magnifying the deficiencies of standardized therapy, which often provide little treatment latitude for accommodating patient physiologic idiosyncrasies. A personalized approach to medicine is not a novel concept. Ever since the scientific community began unraveling the mysteries of the genome, the promise of discarding generic treatment regimens in favor of patient-specific therapies became more feasible and realistic. One of the major scientific impediments of this movement towards personalized medicine has been the need for technological enablement. Nanotechnology is projected to play a critical role in patient-specific therapy; however, this transition will depend heavily upon the evolutionary development of a systems biology approach to clinical medicine based upon “-omic” technology analysis and integration. This manuscript provides a forward looking assessment of the promise of nanomedicine as it pertains to individualized medicine and establishes a technology “snapshot” of the current state of nano-based products over a vast array of clinical indications and range of patient specificity. Other issues such as market driven hurdles and regulatory compliance reform are anticipated to “self-correct” in accordance to scientific advancement and healthcare demand. These peripheral, non-scientific concerns are not addressed at length in this manuscript; however they do exist, and their impact to the paradigm shifting healthcare transformation towards individualized medicine will be critical for its success.

show abstract

Biodistribution study and identification of inflammation sites using 99mTc-labelled stealth pH-sensitive liposomes

Abstract: This result indicates that the 99mTc-SpHL presents a high tropism for inflammatory regions and may be useful as a radiopharmaceutical to identify these foci.

Cited by 23 publications

References 14 publications

Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration

Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration

Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models

Enabling individualized therapy through nanotechnology

Contact Info

Product

Resources

About